| Name | Title | Contact Details |
|---|---|---|
Rakesh Kumar |
Chief Technology Officer | Profile |
HAIMER is a family run, medium sized company located in Igenhausen, Bavaria near Munich, Germany. We design, produce and sell innovative, high precision products for metal cutting as well as for other branches including automotive, aerospace, energy, rail and general machining. In addition to our large offering of tool holders in all popular interfaces and lengths, including our shrinking and balancing machines, as well as our 3-D Sensors and solid carbide cutting tools, our product offering also includes tool presetting machines of HAIMER Microset. Out of approx. 800 employees worldwide, 500 work at our main production facility in Igenhausen together with the most modern of machines and a high level of automation. At our second HAIMER production site in Bielefeld with around 50 employees, HAIMER Microset presetting machines are manufactured. Our experienced, dynamic and highly qualified employees guarantee the well-known and highest quality "made by HAIMER." As an active apprenticeship company with almost 50 apprentices and a high internal acquisition rate, HAIMER is able to secure its future skilled employees and to fulfill its contribution to further educate young adults, as well as securing the future of our German manufacturing location. As the European market leader in the area of tool holding technology, with a daily capacity of max. 4,000 tool holders, keeping the technological edge of our products is very important to us. Because of this, every year we invest between 8 and 10% of our revenue in research and development. Every day we desire to be better and that works perfectly with our corporate philosophy: Quality Wins Imprint Provider/Responsible for the Haimer GmbH website: Haimer GmbH Weiherstr. 21 D-86568 Igenhausen E-mail: haimer@haimer.de Web: www.haimer.com Also: Youtube Xing CEO: Franz Haimer, Claudia Haimer, Andreas Haimer Corporate headquarters: Igenhausen Commercial register: Amtsgericht Augsburg, HRB 8679 VAT ID number: DE 127333346
Auxiant is a Third Party Administrator (TPA) of self-funded benefit plans. Our specialty is customization, technological tools for clients and individuals, and cost-control and health management. We provide administration for over 60,000 employees from our administrative offices in Madison Wisconsin and Cedar Rapids, Iowa. Our Sales offices are in Cedar Rapids, Iowa and Milwaukee, Wisconsin. TPAs are one of the best-kept secrets in the country. Many people do not know TPA firms exist-yet about 2/3 of all employee benefit plans in the U.S. use TPA services. As a TPA, we are dedicated to taking excellent care of the employer and the individuals covered under their employer-sponsored health plans. A health plan is a highly valued component of a companys employment package. With the rising costs of medical care, a health plan has also become a major employer expense. We know how important careful administration of an employer health plan is. We believe it is important to provide our plans with cost-management strategies, while providing plan participants with tools to help them deal with the complexities of health care purchasing. Auxiants Medical Management programs help plan sponsors achieve the lowest medical spend. Auxiant is member of the Society of Professional Benefit Administrators (SPBA) and Society of Self Insured Administrators (SIIA).
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Mold Law Groups litigation platform is a culmination of over 15 years of in-depth research by environmentalists, epidemiologists, toxicologists, medical professionals, Neurotoxicologists, Neuropsychologists, and law firms. Our proven methodology, for the first time, provides litigators the ability to couple the human pathogens in an environment to the direct causation of disease within the human body. The development of this cutting-edge science required an understanding of many different scientific disciplines and medical philosophies to provide a unique and new model for mold litigation. This platform is designed to defend or prosecute property and medical damages caused by mold and microbial exposure. Using precision based DNA-PCR sequencing, bacteria culturing, endotoxin testing, (1—>3)β-D beta glucan and other advanced environmental and medical testing, we leverage cutting edge technology and advanced mold litigation techniques to provide our clients with unparalleled and detailed services found nowhere else in our industry. Mold Law Group offers expert witnesses, consulting services, medical resources, legal resources, and environmental resources. We offer these services nationally and internationally. Mold Law Group is the absolute gold standard when it comes to mold litigation consulting.